StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research report report published on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.
Cyclacel Pharmaceuticals Price Performance
Shares of CYCC opened at $0.30 on Friday. The firm’s 50 day moving average is $0.35 and its 200-day moving average is $0.57. Cyclacel Pharmaceuticals has a 12-month low of $0.29 and a 12-month high of $4.00. The stock has a market capitalization of $1.87 million, a P/E ratio of -0.03 and a beta of 0.28.
Insider Activity
In related news, CEO David E. Lazar sold 194,628,820 shares of Cyclacel Pharmaceuticals stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total value of $5,838,864.60. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 23.97% of the company’s stock.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
See Also
- Five stocks we like better than Cyclacel Pharmaceuticals
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Following Congress Stock Trades
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
